roche holding ag anemia drug mircera wins initial approval in europe roche holding ag received preliminary approval to sell its new anemia drug mircera in europe and said it expects approval in the u s by the end of the year moving the swiss company closer to competing with anemia drug giant amgen inc roche said the european committee for medicinal products for human use is recommending that the european commission grant a marketing license for mircera for the treatment of anemia tied to chronic kidney disease analysts saw the tentative european nod as a good sign of mirceras chances of approval in the u s where the food and drug administration recently delayed its review 
